Home/Pipeline/BASH-003

BASH-003

Alzheimer's Disease

PreclinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Preclinical

Status

Active

Company

Bash Biotech

About Bash Biotech

Bash Biotech is a private, preclinical-stage biotech based in San Francisco, applying a dual-platform approach of AI/ML and systems biology to decode host-microbiome interactions for therapeutic discovery. The company has a nascent pipeline targeting major unmet needs in chronic kidney disease, kidney cancer, Alzheimer's, and Parkinson's disease, all in preclinical development. Founded with $1M in seed funding, it is pre-revenue and focuses on building its proprietary data platforms (iNetModels, GutMicroNet) to drive its drug repositioning and target identification efforts.

View full company profile

Therapeutic Areas

Neurological Diseases Kidney Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active